News Sentiment

PTCT sentiment intelligence

PTC Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 78.59 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-7.4% over one week, -0.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

PTC Therapeutics schedules second-quarter 2026 results webcast conference call

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -7.4% Price reacting lower
Trend fit Trend active -0.5% over four weeks
Fair value 65.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 36
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 11
Investing.com 5
Quartr 4
simplywall.st 4
Seeking Alpha 3
Simply Wall Street 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 19
Analyst action 3
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Bitget Direct company coverage

PTC Therapeutics schedules second-quarter 2026 results webcast conference call

PTC Therapeutics is scheduled to report its second-quarter 2026 financial results on July 30, 2026. A webcast conference call will be held on the same day at 4:30 p.m. ET, with a replay available for 30 days. This news brief was generated by Public Technologies using AI, based on

Tone
Neutral 50/100
Event
Earnings
Published
17 Jul 2026 00:11
Source
Bitget
Investing.com Canada Direct company coverage

Form 4 PTC Therapeutics Inc For: 16 July By Investing.com

This article from Investing.com announces a Form 4 filing for PTC Therapeutics Inc for July 16, 2026. Form 4 filings are statements of changes in beneficial ownership of securities. The article briefly mentions other market news and includes market data and popular articles.

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 21:36
Source
Investing.com Canada
Stock Titan Direct company coverage

PTC Therapeutics (PTCT) CFO auto-sells 3,494 shares to cover RSU taxes

PTC Therapeutics' CFO, Pierre Gravier, automatically sold 3,494 shares of common stock at $80.35 per share on July 14, 2026. This transaction was executed to fulfill tax withholding obligations tied to the vesting of 6,500 RSUs. After this sale, Gravier directly holds 83,986 shar

Tone
Negative 40/100
Event
Market update
Published
16 Jul 2026 21:20
Source
Stock Titan
Market source Direct company coverage

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced it will host a webcast conference call on Thursday, July 30, 2026, at 4:30 p.m. ET to report its second-quarter 2026 financial results. The company will also provide a business update and outlook during the call. Interested parties

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 12:09
Source
Market source
Stock Titan Direct company coverage

PTC Therapeutics Sets July 30 Webcast for Business Update

PTC Therapeutics (NASDAQ: PTCT) announced it will host a webcast conference call on Thursday, July 30, 2026, at 4:30 p.m. ET to report its second quarter 2026 financial results and provide a business and outlook update. Investors can access the live webcast and replay on the comp

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 12:09
Source
Stock Titan
The Globe and Mail Direct company coverage

PTC Therapeutics (PTCT) Gets a Buy from Bank of America Securities

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on PTC Therapeutics (PTCT) with a $95.00 price target. This follows a similar Buy rating from J.P. Morgan, though RBC Capital maintained a Hold rating. The company recently reported a quarterly revenue of $27

Tone
Positive 71/100
Event
Analyst action
Published
16 Jul 2026 11:09
Source
The Globe and Mail
Investing.com Direct company coverage

Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock

Cantor Fitzgerald has reiterated an Overweight rating and a $124 price target for PTC Therapeutics (NASDAQ:PTCT), citing a strong launch for its PKU treatment, Sephience. The firm plans to engage management to discuss Sephience's global expansion, potential FDA dialogue for votop

Tone
Positive 90/100
Event
Analyst action
Published
15 Jul 2026 12:40
Source
Investing.com
Simply Wall Street Direct company coverage

What PTC Therapeutics (PTCT)'s Q1 Beat and Sephience Outlook Shift Mean For Shareholders

PTC Therapeutics reported strong Q1 2026 earnings, exceeding analyst expectations, with an improved outlook for its rare disease therapy Sephience. This positive news, despite pre-planned insider stock sales, supports the company's investment narrative and has led to analyst upgr

Tone
Positive 72/100
Event
Earnings
Published
14 Jul 2026 20:14
Source
Simply Wall Street
Quartr Direct company coverage

PTC Therapeutics (PTCT) Q1 2025 earnings summary

PTC Therapeutics (PTCT) reported strong Q1 2025 results with a revenue of $1.18 billion, largely due to a $986.2 million Novartis upfront payment. The company achieved a net income of $866.6 million, a significant improvement from a net loss in Q1 2024, and ended the quarter with

Tone
Positive 81/100
Event
Earnings
Published
14 Jul 2026 10:14
Source
Quartr
Quartr Direct company coverage

PTC Therapeutics (PTCT) 2024 Wells Fargo Healthcare Conference Summary

PTC Therapeutics (PTCT) presented at the 2024 Wells Fargo Healthcare Conference, highlighting strong financial performance with raised 2024 revenue guidance to $700–$750 million and $1.09 billion in cash. The company provided updates on its pipeline, including three FDA applicati

Tone
Positive 76/100
Event
Earnings
Published
14 Jul 2026 09:40
Source
Quartr
Investing.com Nigeria Direct company coverage

Form 4 PTC Therapeutics Inc For: 13 July By Investing.com

This article announces the filing of Form 4 for PTC Therapeutics Inc. on July 13. It is a very brief news item published by Investing.com, accompanied by a general market overview and links to other news and financial tools. The core content is the notification of the Form 4 fili

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 22:30
Source
Investing.com Nigeria
Investing.com Direct company coverage

Mary L. Smith, director at PTC Therapeutics, sells $1.43m in stock

Mary L. Smith, a director at PTC Therapeutics, sold 15,834 shares of common stock totaling approximately $1.43 million on July 9, 2026, after acquiring the same number of shares through stock option exercises. The sale occurred near the stock's 52-week high, following strong perf

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:40
Source
Investing.com
Stock Titan Direct company coverage

PTC Therapeutics (PTCT) director trades 15,834 shares via option exercise and sale

Mary L. Smith, a director at PTC Therapeutics (PTCT), exercised stock options for 15,834 shares at $42.95 each and subsequently sold all 15,834 shares at $90.00 each on July 9, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in Novembe

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:12
Source
Stock Titan
Stock Titan Direct company coverage

PTC Therapeutics (PTCT) officer sells 2,464 shares after option exercise

Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics (PTCT), exercised stock options to acquire 2,464 common shares at $46.54 and simultaneously sold these shares at a weighted average of $90.25 under a pre-arranged Rule 10b5-1 plan. Following these trans

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:12
Source
Stock Titan
Simply Wall Street Direct company coverage

PTC Therapeutics (PTCT) On Russell Index Inclusion And Pipeline Optimism With Fair Value In Focus

PTC Therapeutics (PTCT) has gained investor attention due to its inclusion in three Russell 2000 Defensive indexes, two FDA New Drug Applications under review, and a potential Phase 3 Huntington's disease program. Despite reporting a loss of US$186.7 million, the company's fair v

Tone
Positive 71/100
Event
Market update
Published
12 Jul 2026 21:10
Source
Simply Wall Street
Quartr Direct company coverage

PTC Therapeutics (PTCT) Q2 2024 earnings summary

PTC Therapeutics reported Q2 2024 total revenue of $187 million, with a 24% year-over-year decline in net product revenue due to lower Translarna and Emflaza sales, but a 44% increase in Evrysdi royalty revenue. The company significantly reduced its net loss to $99.2 million and

Tone
Positive 66/100
Event
Earnings
Published
11 Jul 2026 20:40
Source
Quartr
Quartr Direct company coverage

PTC Therapeutics (PTCT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

This article summarizes PTC Therapeutics' presentation at the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Key highlights include record Q1 product revenue driven by the SEPHIENCE launch, the broad R&D pipeline with ongoing clinical trials, and the significant mar

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 12:39
Source
Quartr
Market source Direct company coverage

Is PTC Therapeutics (PTCT) A Bargain Following Its Russell 2000 Defensive Index Additions?

PTC Therapeutics (PTCT) has been added to three Russell 2000 Defensive indexes, which could influence investor interest. Despite strong recent share price performance and a common narrative suggesting the stock is 9.7% undervalued with a fair value of $93.93, valuation based on t

Tone
Positive 67/100
Event
Market update
Published
11 Jul 2026 08:39
Source
Market source
AlphaStreet Direct company coverage

PTC Therapeutics Drops 5.5% Amid Sector-Wide Selling

PTC Therapeutics saw its share price drop by 5.5% on Friday, closing at $84.65, as part of a broader selloff in the biotechnology sector. The decline was largely attributed to sector-wide pressure rather than any company-specific news, with several peer companies experiencing sim

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 08:39
Source
AlphaStreet
Investing.com Nigeria Direct company coverage

Form 4 PTC Therapeutics Inc For: 8 July By Investing.com

This article reports on a Form 4 filing for PTC Therapeutics Inc for July 8th. Form 4 filings disclose changes in beneficial ownership of company stock by insiders. The brief mention indicates an official financial transaction or holding update related to the company.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:10
Source
Investing.com Nigeria
Stock Traders Daily Direct company coverage

Responsive Playbooks and the PTCT Inflection

This article analyzes PTC Therapeutics Inc. (NASDAQ: PTCT), highlighting a strong sentiment across all horizons supporting an overweight bias. The analysis, generated by AI models, provides three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging)

Tone
Positive 73/100
Event
Market update
Published
09 Jul 2026 13:19
Source
Stock Traders Daily
Moomoo Direct company coverage

PTC Therapeutics(PTCT.US) Officer Sells US$4.09 Million in Common Stock

A PTC Therapeutics officer recently sold 150,000 shares of common stock for a total of $4.09 million. The transaction was disclosed through a Form 4 filing with the SEC.

Tone
Negative 29/100
Event
Market update
Published
08 Jul 2026 22:19
Source
Moomoo
Investing.com Direct company coverage

PTC Therapeutics’ Mark Boulding, exec VP, sells $432,117 in stock

Mark Elliott Boulding, Executive VP and CLO at PTC Therapeutics, Inc., sold 5,079 shares of common stock for $432,117 on July 6, 2026, under a pre-arranged trading plan. Concurrently, he acquired 5,079 shares by exercising stock options for $220,242, increasing his direct holding

Tone
Positive 63/100
Event
Market update
Published
08 Jul 2026 22:10
Source
Investing.com
Investing.com Direct company coverage

Ptc therapeutics tech ops chief sells $4.1m in common stock

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, sold approximately $4.1 million in common stock and acquired $1.8 million worth of stock on July 6 and 7, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. The sales o

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 22:10
Source
Investing.com